{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T20:52:31Z","timestamp":1783975951766,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fayoum University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Hydroxychloroquine is a widely used medication for various clinical conditions mainly rheumatological and dermatological autoimmune diseases e.g. systemic lupus erythematosus, rheumatoid arthritis and psoriasis. While it is considered a safe medication, it is well-established that it can cause retinal toxicity i.e. HCQ maculopathy. Guidelines for HCQ retinal toxicity screening include factors like body weight, daily dose, duration, systemic diseases and retinal diseases. In this case study, we report a specific association between CRAO as a retinal disease and early onset HCQ maculopathy in a SLE patient.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 42-year-old Caucasian female SLE patient presented with a complaint of gradual progressive painless diminution of vision in the left eye that started 16\u00a0months earlier. Clinical evaluation of the patient revealed a history of sudden profound painless diminution of vision in the same eye 18\u00a0months earlier after which the patient experienced only partial improvement of vision. That episode of sudden diminution of vision was attributed to left CRAO, complicating SLE-related thrombophilia, confirmed by fundus fluorescein angiography. Based on that diagnosis, the patient had been prescribed HCQ. At the time of presentation, fundus examination revealed left bull's eye maculopathy and right normal fundus. Therefore, a diagnosis of HCQ maculopathy in the left eye was made after exclusion of other causes of unilateral bull's eye maculopathy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our case study is the first to report an association between CRAO as a specific retinal disease and early onset of HCQ maculopathy in a SLE patient. The unilateral bull's eye presentation which occurred in the eye with CRAO after only 16\u00a0months of HCQ treatment highly suggests that CRAO is probably the cause of such unusually early maculopathy. This case report highlights the importance of retinal diseases as risk factors for HCQ maculopathy. It also points out the lack of specific evidence concerning the association between specific retinal diseases and HCQ maculopathy.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12886-022-02657-8","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T16:20:12Z","timestamp":1668442812000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Early onset monocular hydroxychloroquine maculopathy in a systemic lupus erythematosus patient with history of central retinal artery occlusion: a case report"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7193-9512","authenticated-orcid":false,"given":"Ahmed","family":"Ameen Ismail","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherin Hassan","family":"Sadek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragai Magdy","family":"Hatata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,14]]},"reference":[{"issue":"7","key":"2657_CR1","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1177\/0961203320919499","volume":"29","author":"PM Aduriz-Lorenzo","year":"2020","unstructured":"Aduriz-Lorenzo PM, Aduriz-Llaneza P, Araiz-Iribarren J, Khamashta MA. Current opinion on hydroxychloroquine-related retinal toxicity screening: where do we stand now? Lupus. 2020;29(7):671\u20135.","journal-title":"Lupus"},{"issue":"7","key":"2657_CR2","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/S0161-6420(03)00409-3","volume":"110","author":"I Mavrikakis","year":"2003","unstructured":"Mavrikakis I, Sfikakis PP, Mavrikakis E, Rougas K, Nikolaou A, Kostopoulos C, et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmol. 2003;110(7):1321\u20136.","journal-title":"Ophthalmol"},{"issue":"12","key":"2657_CR3","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","volume":"132","author":"RB Melles","year":"2014","unstructured":"Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132(12):1453\u201360.","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"2657_CR4","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jfo.2017.08.002","volume":"40","author":"A Couturier","year":"2017","unstructured":"Couturier A, Giocanti-Aur\u00e9gan A, Dupas B, Girmens JF, Le Mer Y, Massamba N, et al. Update on recommendations for screening for hydroxychloroquine retinopathy. J Fr Ophtalmol. 2017;40(9):793\u2013800.","journal-title":"J Fr Ophtalmol"},{"issue":"28","key":"2657_CR5","first-page":"1","volume":"2022","author":"RA Alieldin","year":"2022","unstructured":"Alieldin RA, Boonarpha N, Saedon H. Outcomes of screening for hydroxychloroquine retinopathy at the Manchester Royal Eye Hospital: 2 years\u2019 audit. Eye. 2022;2022(28):1\u20136.","journal-title":"Eye"},{"issue":"8","key":"2657_CR6","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.2147\/OPTH.S66527","volume":"25","author":"DJ Browning","year":"2014","unstructured":"Browning DJ, Lee C. Relative sensitivity and specificity of 10\u20132 visual fields, multifocal electroretinography, and spectral domain optical coherence tomography in detecting hydroxychloroquine and chloroquine retinopathy. Clin Ophthalmol. 2014;25(8):1389\u201399.","journal-title":"Clin Ophthalmol"},{"issue":"7","key":"2657_CR7","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s00296-021-04868-6","volume":"41","author":"R Muller","year":"2021","unstructured":"Muller R. Systemic toxicity of chloroquine and hydroxychloroquine: prevalence, mechanisms, risk factors, prognostic and screening possibilities. Rheumatol Int. 2021;41(7):1189\u2013202.","journal-title":"Rheumatol Int"},{"issue":"7","key":"2657_CR8","doi-asserted-by":"publisher","first-page":"570","DOI":"10.4103\/0301-4738.167120","volume":"63","author":"HK Pandya","year":"2015","unstructured":"Pandya HK, Robinson M, Mandal N, Shah VA. Hydroxychloroquine retinopathy: A review of imaging. Indian J Ophthalmol. 2015;63(7):570.","journal-title":"Indian J Ophthalmol"},{"issue":"6","key":"2657_CR9","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","volume":"123","author":"MF Marmor","year":"2016","unstructured":"Marmor MF, Kellner U, Lai TYY, Melles RB, Mieler WF, Lum F. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmol. 2016;123(6):1386\u201394.","journal-title":"Ophthalmol"},{"issue":"1","key":"2657_CR10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/ceo.12997","volume":"46","author":"A Agarwal","year":"2018","unstructured":"Agarwal A, Karkhur S, Aggarwal K, Invernizzi A, Singh R, Dogra MR, et al. Epidemiology and clinical features of inflammatory retinal vascular occlusions: pooled data from two tertiary-referral institutions. Clin Experiment Ophthalmol. 2018;46(1):62\u201374.","journal-title":"Clin Experiment Ophthalmol"},{"issue":"9","key":"2657_CR11","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/art.40930","volume":"71","author":"M Aringer","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 EULAR\/ACR Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol (Hoboken, NJ). 2019;71(9):1400.","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"2657_CR12","doi-asserted-by":"publisher","unstructured":"Ponticelli C, Moroni G. Hydroxychloroquine in systemic lupus erythematosus (SLE). http:\/\/dx.doi.org\/https:\/\/doi.org\/10.1080\/1474033820171269168. 2016;16(3):411\u20139.","DOI":"10.1080\/1474033820171269168"},{"issue":"5","key":"2657_CR13","first-page":"329","volume":"24","author":"LC Wei","year":"2001","unstructured":"Wei LC, Chen SN, Ho CL, Kuo YH, Ho JD. Progression of hydroxychloroquine retinopathy after discontinuation of therapy: case report. Chang Gung Med J. 2001;24(5):329\u201334.","journal-title":"Chang Gung Med J"},{"issue":"22","key":"2657_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025688","volume":"100","author":"G Wang","year":"2021","unstructured":"Wang G, Zhuo N, Liao Z, Qi W, Tian F, Wen Z, et al. Retinal toxicity caused by hydroxychloroquine in patients with systemic lupus erythematosus: A case report. Medicine (Baltimore). 2021;100(22): e25688.","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"2657_CR15","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1002\/1529-0131(200108)44:8<1959::AID-ART334>3.0.CO;2-A","volume":"44","author":"AE Warner","year":"2001","unstructured":"Warner AE. Early Hydroxychloroquine Macular Toxicity. Arthritis Rheum. 2001;44(8):1959\u201361.","journal-title":"Arthritis Rheum"},{"key":"2657_CR16","doi-asserted-by":"publisher","unstructured":"Cerri E, Origlia N, Falsini B, Barloscio D, Fabiani C, Sans\u00f2 M, et al. Conjunctivally Applied BDNF Protects Photoreceptors from Light-Induced Damage. Transl Vis Sci Technol.\u00a02015;4(6):1. https:\/\/doi.org\/10.1167\/tvst.4.6.1.","DOI":"10.1167\/tvst.4.6.1"},{"issue":"1","key":"2657_CR17","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.brainres.2006.10.031","volume":"1129","author":"S Azadi","year":"2007","unstructured":"Azadi S, Johnson LE, Paquet-Durand F, Perez MTR, Zhang Y, Ekstr\u00f6m PAR, et al. CNTF+BDNF treatment and neuroprotective pathways in the rd1 mouse retina. Brain Res. 2007;1129(1):116\u201329.","journal-title":"Brain Res"},{"issue":"2","key":"2657_CR18","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.preteyeres.2011.11.005","volume":"31","author":"R Wen","year":"2012","unstructured":"Wen R, Tao W, Li Y, Sieving PA. CNTF and retina. Prog Retin Eye Res. 2012;31(2):136\u201351.","journal-title":"Prog Retin Eye Res"},{"issue":"5","key":"2657_CR19","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1089\/jop.2016.0121","volume":"33","author":"P Baranov","year":"2017","unstructured":"Baranov P, Lin H, McCabe K, Gale D, Cai S, Lieppman B, et al. A Novel Neuroprotective Small Molecule for Glial Cell Derived Neurotrophic Factor Induction and Photoreceptor Rescue. J Ocul Pharmacol Ther. 2017;33(5):412\u201322.","journal-title":"J Ocul Pharmacol Ther"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-022-02657-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-022-02657-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-022-02657-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T16:22:23Z","timestamp":1668442943000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-022-02657-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,14]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2657"],"URL":"https:\/\/doi.org\/10.1186\/s12886-022-02657-8","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,14]]},"assertion":[{"value":"15 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The patient consented to participate in this case report as part of her clinical ophthalmological follow-up.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"A written consent of the patient's approval of publication of anonymized data was obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"434"}}